Drug Search Results
More Filters [+]

Ethambutol

Alternative Names: ethambutol, myambutol
Latest Update: 2024-10-01
Latest Update Note: Clinical Trial Update

Product Description

Ethambutol is a medication used in the management and treatment of tuberculosis. It is a bacteriostatic drug that inhibits cell wall synthesis. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK559050/)

Mechanisms of Action: Arabinosyl Transferase Inhibitor,Cell Wall Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Insmed
Company Location: BRIDGEWATER NJ 08807
Company CEO: William H. Lewis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ethambutol

Countries in Clinic: Argentina, Australia, Austria, Denmark, Germany, Israel, Italy, Japan, Korea, New Zealand, Spain, Taiwan, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Communicable Diseases|Mycobacterium Infections|Mycobacterium Infections, Nontuberculous|Mycobacterium avium-intracellulare Infection|Nontuberculous Mycobacterial Lung Disease

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MAC-LD

P3

Active, not recruiting

Mycobacterium avium-intracellulare Infection|Mycobacterium Infections

2025-07-17

SPR720-102

P1

Completed

Healthy Volunteers

2024-01-30

28%

SPR720-102

P1

Completed

Healthy Volunteers

2024-01-30

28%

ARISE

P3

Completed

Mycobacterium avium-intracellulare Infection|Mycobacterium Infections, Nontuberculous|Communicable Diseases

2023-05-09

ARISE

P3

Active, not recruiting

Nontuberculous Mycobacterial Lung Disease

2022-08-22

Recent News Events